Apellis Pharmaceuticals, Inc. (APLS) Tops Q2 EPS by 15c

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q2 EPS of ($0.33), $0.15 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $178.49 million versus the consensus estimate of $186.76 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.

You May Also Be Interested In

• WD-40 Co. (WDFC) Tops Q3 EPS by 76c; offers guidance
• Sempra names new CFO and SoCalGas CEO amid infrastructure deal
• Thermo Fisher Scientific (TMO) Declares $0.47 Quarterly Dividend; 0.4% Yield